TY - JOUR
T1 - Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications
AU - Godman, Brian
AU - Hill, Andrew
AU - Simoens, Steven
AU - Selke, Gisbert
AU - Selke Krulichová, Iva
AU - Zampirolli Dias, Carolina
AU - Martin, Antony P
AU - Oortwijn, Wija
AU - Timoney, Angela
AU - Gustafsson, Lars
AU - Voncina, Luka
AU - Kwon, Hye-Young
AU - Gulbinovic, Jolanta
AU - Gotham, Dzintars
AU - Wale, Janet
AU - Silva, Wânia Cristina da
AU - Bochenek, Tomasz
AU - Allocati, Eleonora
AU - Kurdi, Amanj
AU - Ogunleye, Olayinka O
AU - Meyer, Johanna C
AU - Hoxha, Iris
AU - Malaj, Admir
AU - Hierländer, Christian
AU - Sauermann, Robert
AU - Hamelinck, Wouter
AU - Petrova, Guenka
AU - Laius, Ott
AU - Langner, Irene
AU - Yfantopoulos, John
AU - Joppi, Roberta
AU - Jakupi, Arianit
AU - Greiciute-Kuprijanov, Ieva
AU - Vella Bonanno, Patricia
AU - Piepenbrink, Jf Hans
AU - de Valk, Vincent
AU - Wladysiuk, Magdalene
AU - Marković-Peković, Vanda
AU - Mardare, Ileana
AU - Fürst, Jurij
AU - Tomek, Dominik
AU - Obach Cortadellas, Mercè
AU - Zara, Corinne
AU - Pontes, Caridad
AU - McTaggart, Stuart
AU - Laba, Tracey-Lea
AU - Melien, Øyvind
AU - Wong-Rieger, Durhane
AU - Bae, SeungJin
AU - Hill, Ruaraidh
PY - 2021/2/4
Y1 - 2021/2/4
N2 - - CLEAN VERSION Introduction: There are growing concerns among European health authorities regarding increasing prices for new cancer medicines, prices not necessarily linked to health gain and the implications for the sustainability of their healthcare systems. Areas covered: Narrative discussion principally among payers and their advisers regarding potential approaches to the pricing of new cancer medicines. Expert commentary: A number of potential pricing approaches are discussed including minimum effectiveness levels for new cancer medicines, managed entry agreements, multicriteria decision analyses (MCDAs), differential/tiered pricing, fair pricing models, amortization models as well as de-linkage models. We are likely to see a growth in alternative pricing deliberations in view of ongoing challenges including the considerable number of new cancer medicines in development including new gene therapies and being launched with uncertainty regarding their value, continued high prices coupled with the extent of confidential discounts for reimbursement; however, balanced against the need for new cancer medicines. This will lead to greater scrutiny over the prices of patent oncology medicines as more standard medicines lose their patent, calls for greater transparency as well as new models including amortization models. We will be monitoring these developments.
AB - - CLEAN VERSION Introduction: There are growing concerns among European health authorities regarding increasing prices for new cancer medicines, prices not necessarily linked to health gain and the implications for the sustainability of their healthcare systems. Areas covered: Narrative discussion principally among payers and their advisers regarding potential approaches to the pricing of new cancer medicines. Expert commentary: A number of potential pricing approaches are discussed including minimum effectiveness levels for new cancer medicines, managed entry agreements, multicriteria decision analyses (MCDAs), differential/tiered pricing, fair pricing models, amortization models as well as de-linkage models. We are likely to see a growth in alternative pricing deliberations in view of ongoing challenges including the considerable number of new cancer medicines in development including new gene therapies and being launched with uncertainty regarding their value, continued high prices coupled with the extent of confidential discounts for reimbursement; however, balanced against the need for new cancer medicines. This will lead to greater scrutiny over the prices of patent oncology medicines as more standard medicines lose their patent, calls for greater transparency as well as new models including amortization models. We will be monitoring these developments.
U2 - 10.1080/14737167.2021.1884546
DO - 10.1080/14737167.2021.1884546
M3 - Artículo
C2 - 33535841
JO - Expert Review of Pharmacoeconomics and Outcomes Research
JF - Expert Review of Pharmacoeconomics and Outcomes Research
SN - 1473-7167
ER -